Natural Drug Treatments Offer Promise, Potential as Savvy Drug Developers Recognize True Opportunities
- NetworkNewsWire Editorial Coverage
NEW YORK, May 20, 2021 /PRNewswire/ Before government legislation brought the world of psychedelic drug compounds to a halt, promising research was being done in the space. As researchers and scientists took closer looks at substances such as psilocybin, ketamine, DMT (dimethyltryptamine), LSD (lysergic acid diethylamide) and more, the potential for the compounds appeared to be widespread and even life-changing for many who struggled with notoriously difficult diseases such as depression, addiction, PTSD and more. And then the Federal Comprehensive Drug Abuse Prevention and Control Act of 1970, known as the Controlled Substance Act, took effect. For decades, the promise of these substances has remained ignored. However, with recent changes in legal guidelines and swings in public opinion, astute researchers - and companies - are showing renew
Share this article
Share this article
NEWTOWN, Pa., Jan. 26, 2021 /PRNewswire/ Monica E. Luchi, MD, FACR, MBA, has been named a partner at The Bracken Group (TBG), a consultancy focused on the life sciences. We are so pleased that Monica has elected to join us, said Colin G. Miller, co-founder and managing partner of TBG. She not only brings extensive experience as a pharmaceutical physician and chief medical officer, but she is also a practicing rheumatologist at the University of Pennsylvania.
Dr. Luchi has been a board-certified rheumatologist for more than 25 years and has more than 20 years experience in the pharmaceutical industry. Immediately prior to joining TBG, she was senior vice president of Clinical Research and Development at Sorrento Therapeutics, Inc. Previously, she held positions of increasing responsibility at Novartis, Incyte, Mesoblast, and Immune Pharmaceuticals in clinical development, translational medicine, and strategic planning, as well as key b